Q2
CRVS — Q2 2026 Financial Report Analysis
Corvus doubled its quarterly R&D spend to $16.0M as soquelitinib's Phase 3 lymphoma and Phase 2 eczema trials enrolled, widening the net loss to $18.0M, while $215.2M of cash from January's $189.4M stock sale keeps runway into Q2 2028.